Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Adhesion of Rivastigmine Transdermal Patch
NCT07464340Phase 1Completed
- Sponsor
- Zodiac Produtos Farmacêuticos
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised trial of rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) (2 arms), sponsored by Zodiac Produtos Farmacêuticos. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Concentration-Time Curve from time zero to the last measurable concentration at 48 hours and 3 more. Started May 2023; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT07464340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07464340.